NCT/Study#
NA /
P153CV-RAS-001
Phase I Study Dose Finding Study To Evaluate Safety, Reactogenicity And Immunogenicity Of CV09040102 RAS G12D Mrna Vaccine In HLA- Selected Patients With Pancreatic Cancer Or Colorectal Cancer Harboring The RAS G12D Mutation
DISEASE GROUP:
Phase 1 Clinical Trials
current phase:
Phase I
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information:
Call 201-518-3587
